Mirdametinib

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 58 publications

TEAD inhibitors re-sensitize drug-resistant NF1 MPNST cells to MEK inhibitors.

TEAD inhibitors re-sensitize drug-resistant NF1 MPNST cells to MEK inhibitors.

Journal: microPublication biology
Published: April 22, 2026

Mirdametinib and abemaciclib cooperate in atypical teratoid rhabdoid tumor to decrease proliferation and suppress tumor growth.

Mirdametinib and abemaciclib cooperate in atypical teratoid rhabdoid tumor to decrease proliferation and suppress tumor growth.

Journal: bioRxiv : the preprint server for biology
Published: April 03, 2026

Patient-reported pain outcomes following MEK inhibitor therapy in neurofibromatosis type 1-associated plexiform neurofibromas: A systematic review and meta-analysis.

Patient-reported pain outcomes following MEK inhibitor therapy in neurofibromatosis type 1-associated plexiform neurofibromas: A systematic review and meta-analysis.

Journal: Clinical neurology and neurosurgery
Published: March 31, 2026

Mechanical Stiffening Promotes Growth, Invasion-Associated Phenotypes, and Reduced Selumetinib Sensitivity in 3D Plexiform Neurofibroma Cultures.

Mechanical Stiffening Promotes Growth, Invasion-Associated Phenotypes, and Reduced Selumetinib Sensitivity in 3D Plexiform Neurofibroma Cultures.

Journal: Cells
Published: March 27, 2026

Class-level DILI saturation and hERG-driven risk stratification among 2024-2025 FDA-approved kinase inhibitors: an in silico multi-platform safety analysis.

Class-level DILI saturation and hERG-driven risk stratification among 2024-2025 FDA-approved kinase inhibitors: an in silico multi-platform safety analysis.

Journal: Investigational new drugs
Published: March 16, 2026

Mirdametinib in symptomatic neurofibromatosis type 1 plexiform neurofibromas.

Mirdametinib in symptomatic neurofibromatosis type 1 plexiform neurofibromas.

Journal: Expert review of anticancer therapy
Published: March 12, 2026

MEK inhibitor Mirdametinib promotes fracture healing in osteofibrous dysplasia RASopathy.

MEK inhibitor Mirdametinib promotes fracture healing in osteofibrous dysplasia RASopathy.

Journal: The Journal of clinical investigation
Published: February 26, 2026

Mechanical Stiffening Promotes Growth, Invasion, and Mitogen-Activated Protein Kinase Kinase (MEK) Inhibitor Resistance in 3D Plexiform Neurofibroma Cultures.

Mechanical Stiffening Promotes Growth, Invasion, and Mitogen-Activated Protein Kinase Kinase (MEK) Inhibitor Resistance in 3D Plexiform Neurofibroma Cultures.

Journal: bioRxiv : the preprint server for biology
Published: February 09, 2026

Properties of FDA-approved small molecule protein kinase inhibitors: A 2026 update.

Properties of FDA-approved small molecule protein kinase inhibitors: A 2026 update.

Journal: Pharmacological research
Published: January 20, 2026

Prolonged Mitogen-Activated Protein Kinase Kinase (MEK) Inhibition Induces Increase in Proteolysis and Compensatory Phosphorylation of MEK and Protein Kinase B (AKT) in Plexiform Neurofibroma Cells.

Prolonged Mitogen-Activated Protein Kinase Kinase (MEK) Inhibition Induces Increase in Proteolysis and Compensatory Phosphorylation of MEK and Protein Kinase B (AKT) in Plexiform Neurofibroma Cells.

Journal: Cells
Published: January 05, 2026

Trametinib and Fimepinostat Induce Malignant Peripheral Nerve Sheath Tumor Cell Death In Vitro.

Trametinib and Fimepinostat Induce Malignant Peripheral Nerve Sheath Tumor Cell Death In Vitro.

Journal: Cancers
Published: December 05, 2025

Hidden-driver inference reveals synergistic brain-penetrant therapies for medulloblastoma.

Hidden-driver inference reveals synergistic brain-penetrant therapies for medulloblastoma.

Journal: bioRxiv : the preprint server for biology
Published: December 03, 2025
Showing 1-12 of 58

Last Updated: 09/26/2026